The first paper showed that AC133+ (a glycosylation-dependent epitope of CD133 that marks stem and progenitor cells) AML cells overexpressed and released WNT10B into the microenvironment of AML patients. The gene discussed is PROM1; the disease is acute myeloid leukemia.